COVID-19 vaccine - Curative Biotechnology
Latest Information Update: 06 Oct 2022
At a glance
- Originator Curative Biotechnology
- Class COVID-19 vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 06 Oct 2022 Curative Biotechnology plans to submit phase I/II IND for COVID-2019 infections (Prevention) in USA, by 2024 (Curative Biotech pipeline, October 2022)
- 07 Oct 2021 Curative Biotechnology in-licenses IMT 504 as an adjuvant from Mid-Atlantic BioTherapeutics
- 07 Oct 2021 Early research in COVID-2019 infections (Prevention) in USA (unspecified route)